Matinas BioPharma Announces Issuance of Key U.S. Patent for Prescription-Only Next Generation Omega-3 MAT9001

- October 18th, 2018

Matinas BioPharma (NYSE:MTNB), a clinical-stage biopharmaceutical company, announced today that the U.S. Patent and Trademark Office issued U.S. Patent No. 10,058,521 entitled, “Omega-3 pentaenoic acid compositions and methods of use” to the Company. As quoted in the press release: The issued patent claims cover the Company’s proprietary methods relating to reducing triglyceride levels, total cholesterol, VLDL-cholesterol or … Continued

Matinas BioPharma (NYSE:MTNB), a clinical-stage biopharmaceutical company, announced today that the U.S. Patent and Trademark Office issued U.S. Patent No. 10,058,521 entitled, “Omega-3 pentaenoic acid compositions and methods of use” to the Company.

As quoted in the press release:

The issued patent claims cover the Company’s proprietary methods relating to reducing triglyceride levels, total cholesterol, VLDL-cholesterol or apolipoprotein C-III by administering a pharmaceutical composition comprising omega-3 fatty acids comprising eicosapentaenoic acid (EPA) and docosapentaenoic acid (DPA).

“Recent developments in the cardiovascular space have placed renewed focus on MAT9001, our proprietary and purposefully designed omega-3 product. Over the past few years, we continued to be diligent in the prosecution of important intellectual property covering our MAT9001 product and the ongoing expansion of our intellectual property portfolio is an integral aspect of our development strategy. Given the clinical data generated from a head-to-head study of MAT9001 demonstrating superiority versus Vascepa® (icosapent ethyl) in reducing triglycerides, total and non-HDL cholesterol, apolipoproteins and PCSK9 levels, we are very excited about the prospects for our potential best-in-class drug in this emerging drug class. We are committed to further exploring a variety of interesting and value-creating opportunities for the development and ultimate commercialization of MAT9001,” commented Jerome D. Jabbour, Chief Executive Officer of Matinas.

Click here to read the full press release.

Find out what experts are saying about the future of cannabis

 
Read our 2019 conference report today
 

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select None
Select All

Leave a Reply